Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.
Deborah Birx enters new phase as biotech CEO; Verastem chief announces his retirement
→ After entering the public consciousness with the White House Coronavirus Task Force and embarking on a subsequent book tour, Deborah Birx has replaced Brian